cover of episode Roche CEO: Future of cancer treatment, AI in Medicine and Trial Challenges

Roche CEO: Future of cancer treatment, AI in Medicine and Trial Challenges

2024/11/20
logo of podcast In Good Company with Nicolai Tangen

In Good Company with Nicolai Tangen

Chapters

Thomas Schinecker discusses the factors contributing to Basel's emergence as a leading biopharma hub, including its historical roots in the chemical industry, strategic location in the center of Europe, and the presence of a robust ecosystem with top universities and educational systems.
  • Basel's history in the chemical industry laid the foundation for its biopharma growth.
  • Strategic location in the center of Europe attracts global talent.
  • Ecosystem includes top universities and educational systems fostering innovation.

Shownotes Transcript

What’s next for cancer treatment and personalized medicine? How is AI reshaping the future of drug discovery? And can Europe keep pace with China’s rapid rise in health care innovation? In this episode, Nicolai welcomes Thomas Schinecker, CEO of Roche, one of the world’s largest health care companies. They discuss Roche’s leadership in cancer treatment, breakthroughs in diagnostics, and the impact of cutting-edge R&D in areas like precision medicine and AI. Schinecker also shares his views on the rapid growth of China’s pharma industry and the challenges Europe faces in keeping up with global clinical trials.

The production team for this episode includes Isabelle Karlsson and PLAN-B's Niklas Figenschau Johansen, Sebastian Langvik-Hansen and Pål Huuse. Background research was conducted by Sara Arnesen.

Hosted on Acast. See acast.com/privacy) for more information.